Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma

International Journal of Clinical Oncology

Volumn 19, Issue 3, 2014, Pages 516-522

  Naiki, Taku ^a   Kawai, Noriyasu ^a   Hashimoto, Yoshihiro ^a   Okamura, Takehiko ^b   Ando, Ryosuke ^b   Yasui, Takahiro ^a   Okada, Atsushi ^a   Etani, Toshiki ^a   Tozawa, Keiichi ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b ANJO KOSEI HOSPITAL   (Japan)

Author keywords

Metastasis; Second line chemotherapy; Urothelial carcinoma

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; TAXOID;

ADULT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SCREENING; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER DYSFUNCTION; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; TAXOIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM; YOUNG ADULT;

EID: 84903316928     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0574-1     Document Type: Article

References (27)

1. Logothetis CJ, Dexeus FH, Finn L et al (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055 (Pubitemid 20200193)
2. Saxman SB, Propert KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564-2569 (Pubitemid 27289886)
3. Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50-54 (Pubitemid 41814532)
4. Kuroda M, Kotake T, Akaza H et al (1998) Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Jpn J Clin Oncol 28:497-501 (Pubitemid 128527328)
5. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
6. von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608 (Pubitemid 46224062)
7. Sternberg CN, Calabro F, Pizzocaro G et al (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92:2993-2998 (Pubitemid 33136193)
8. Kanai K, Kikuchi E, Ohigashi T et al (2008) Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol 13:510-514
9. Albers P, Park SI, Niegisch G et al (2011) Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 22:288-294
10. Suyama T, Ueda T, Fukasawa S et al (2009) Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 39:244-250
11. Ikeda M, Matsumoto K, Tabata K et al (2011) Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Jpn J Clin Oncol 41:1214-1220
12. Kouno T, Ando M, Yonemori K et al (2007) Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol 52:1115-1122 (Pubitemid 47332041)
13. Vaishampayan UN, Faulkner JR, Small EJ et al (2005) Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 104:1627-1632 (Pubitemid 41437425)
14. Soga N, Onishi T, Arima K et al (2007) Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int J Urol 14:828-832 (Pubitemid 47313275)
15. Lin CC, Hsu CH, Huang CY et al (2007) Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 18:487-491 (Pubitemid 46712413)
16. Pectasides D, Aravantinos G, Kalofonos H et al (2001) Combination chemotherapy with gemcitabine and ifosfamide as secondline treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 12:1417-1422 (Pubitemid 33100248)
17. Pagliaro LC, Millikan RE, Tu SM et al (2002) Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20:2965-2970 (Pubitemid 34728891)
18. Kitamura H, Taguchi K, Kunishima Y et al (2011) Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group. Cancer Sci 102:1171-1175
19. Lavelle F, Bissery MC, Combeau C et al (1995) Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22:3-16
20. Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362 (Pubitemid 30415821)
21. Dancey J, Shepherd FA, Gralla RJ et al (2004) Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 43:183-194 (Pubitemid 38114747)
22. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103 (Pubitemid 30324363)
23. Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682-1691 (Pubitemid 39585637)
24. Dreicer R, Manola J, Schneider DJ et al (2003) Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97:2743-2747 (Pubitemid 36605141)
25. Gitlitz BJ, Baker C, Chapman Y et al (2003) A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98:1863-1869 (Pubitemid 37310229)
26. Dumez H, Martens M, Selleslach J et al (2007) Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anticancer Drugs 18:211-218 (Pubitemid 44967431)
27. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247